Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (7322)	12/17/1999 3:33:00 PM
From: NeuroInvestment	Read Replies (2) \| Respond to of 9719

Thank you for the invitation, Rick, I do not believe I have ever visited this thread before. Re: the three neuro companies mentioned (briefly, since I am assembling the 'NI Millenial Overview Issue'--that's tongue in cheek, not grandiose): Synaptic: With all the partners save for Grunenthal having walked away, intent on playing with their receptor toys at their own houses, Synaptic is a niche forlorn. Big Pharma is awash in targets, and until they need more, it's hard to see SNAP's narrow field of expertise coming into favor. A smart Big Pharma would buy them to save for 2001. Cambridge Neuro: Trying to take their GGF2/MS and neuropathic pain programs far enough alone so someone will buy them out. Cortex: Very quietly, Cortex's Ampakine platform is getting attention from prospective partners... I expect a couple of partnerships in 2000--and they may end up the year in the black. Not bad, considering they were running on fumes by the time Organon finalized the first deal last January. NeuroInvestment (www.neuroinvestment.com)